Coagulation and Clotting Tests

Coagulation and Clotting Tests explains the blood tests used to evaluate bleeding risk, abnormal clotting, anticoagulant treatment, and clotting factor function. These tests help show how quickly blood forms a clot, whether key clotting proteins are present, and whether medicines such as warfarin or heparin are working safely. This category covers routine screening tests, specialized factor tests, platelet function studies, inherited clotting disorders, acquired bleeding problems, and follow-up testing for abnormal PT, INR, aPTT, fibrinogen, D-dimer, and related results. Start with the coagulation panel test to understand how PT, INR, aPTT, fibrinogen, and D-dimer fit together. This guide is the best overview for readers who have several clotting results on one report. The prothrombin time normal range article explains PT reference values, what prolonged PT means, and how PT reflects clotting factors I, II, V, VII, and X. The INR normal range guide focuses on standardized PT results, especially for people taking warfarin. It explains normal INR, therapeutic INR targets, and why high or low INR results matter. The aPTT normal range article explains the intrinsic and common clotting pathways. It is useful when a report shows prolonged aPTT, suspected heparin effect, or possible clotting factor deficiency. The D-dimer blood test guide explains why D-dimer rises when clots form and break down. It also covers common causes of high D-dimer, including blood clots, inflammation, infection, surgery, pregnancy, and serious illness. The fibrinogen blood test article explains the clotting protein that becomes fibrin, the mesh that stabilizes clots. It covers normal ranges, low fibrinogen and bleeding risk, and high fibrinogen as an inflammation-related finding. The Anti-Xa therapeutic range guide explains heparin monitoring, including unfractionated heparin and low molecular weight heparin. It is especially helpful when aPTT is unreliable or precise anticoagulant monitoring is needed. The lupus anticoagulant test article explains a confusing result: a “lupus anticoagulant” can prolong clotting tests in the lab but increase clot risk in the body. It also connects to antiphospholipid syndrome and pregnancy loss evaluation. The von Willebrand disease panel guide covers vWF antigen, vWF activity, and factor VIII. It helps readers understand common testing for easy bruising, heavy menstrual bleeding, frequent nosebleeds, and bleeding after dental work or surgery. The mixing study test article explains how clinicians investigate prolonged PT or aPTT. It shows how mixing patient plasma with normal plasma helps separate clotting factor deficiency from inhibitors or anticoagulant effects.